Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide

Bioscience Reports

Volumn 22, Issue 5-6, 2002, Pages 523-528

  Gault, V A ^a   Harriott, P ^b   Flatt, P R ^a   O'Harte, F P M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bioactive domains; BRIN BD11 cells; cAMP; GIP; Insulin secretion

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AGONIST; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLONAL VARIATION; DRUG POTENCY; EVALUATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; PANCREAS ISLET BETA CELL;

ANIMALS; BINDING SITES; CELL LINE; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 0242432370     PISSN: 01448463     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022073819618     Document Type: Article

References (13)

1. Brown, J. C., Dahl, M., Kwauk, S., McIntosh, C. H. S., Otte, S. C., and Pederson, R. A. (1981) Actions of GIP. Peptides Suppl. 2:241-245.
2. Creutzfeldt, W. (2001) The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109:S288-S303.
3. Deacon, C. F., Danielsen, P., Karlskov, L., Olesen, M., and Holst, J. J. (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects on anesthetized pigs. Diabetes 50:1588-1597.
4. 3)GIP analogue and GIP(3-42) on cyclic AMP production and insulin secretion. Diabetologia 44:A195.
5. Gault, V. A., O'Harte, F. P. M., Harriott, P., and Flatt, P. R. (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290:1420-1426.
6. Gremlich, S., Porret, A., Hani, E. H., Cherif, D., Vionnet, N., Froguel, P., and Thorens, B. (1995) Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202 1208.
7. Hinke, S. A. et al. (2001) Identification of a bioactive domain in the amino terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim. Biophys. Acta 1547:143-155.
8. Maletti, M., Carlquist, M., Portha, B., Kergoat, M., Mutt, V., and Rosselin, G. (1986) Structural requirements for gastric inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release. Peptides 7:75-78.
9. McClenaghan, N. H. et al. (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45:1132-1140.
10. Morgan, L. M. (1996) The metabolic role of GIP: physiology and pathology. Biochem. Soc. Trans. 24:585-591.
11. Morrow, G. W. et al. (1996) The insulinotropic region of gastric inhibitory polypeptide; fragment analysis suggests the bioactive site lies between residues 19 and 30. Can. J. Physiol. Pharmacol. 74:65-72.
12. O'Harte, F. P. M., Abdel-Wahab, Y. H. A., Conlon, J. M., and Flatt, P. R. (1998) Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim. Biophys. Acta 1425:319-327.
13. Schmidt, W. E., Siegel, E. G., Kümmel, H., Gallwitz, B., and Creutzfeldt, W. E. (1987) Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinol. 120:835-837.